Want to see BLTE full AI Analyst Report?
BLTE Stock Chart & Stats
$165.45
-$1.45(-2.47%)
At close: 4:00 PM EST
$165.45
-$1.45(-2.47%)
Day’s Range― - ―
52-Week Range$59.06 - $200.00
Previous CloseN/A
Volume15.47K
Average Volume (3M)64.23K
Market Cap
$6.10B
Enterprise Value$5.59B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 12, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.55
Shares Outstanding39,965,313
10 Day Avg. Volume75,810
30 Day Avg. Volume64,229
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)6.96
Price to Sales (P/S)0.00
P/FCF Ratio-144.35
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-58.52
Forecast
1Y Price Target
$216.20Price Target Upside30.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.19
Revenue Forecast (FY)$22.50M
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength And Cash RunwayA very large cash position combined with minimal debt provides multi-year runway to complete the NDA, fund commercial launch preparations and ongoing trials without immediate financing. This materially lowers near-term dilution risk and supports sustained R&D and commercialization investments.
Regulatory Progress: Phase 3 Report And Rolling NDAMoving from late-stage trials to a rolling NDA is a structural shift from development toward regulatory review and potential approval. Completing the filing by Q2 2026 crystallizes the regulatory path and increases the odds of becoming a first-approved therapy in Stargardt disease.
Commercial Buildout And Manufacturing ReadinessEarly investment in commercial leadership, market access and manufacturing capacity creates durable launch capabilities. Having teams and supply-chain plans in place reduces execution risk and shortens time-to-market if regulatory approval is received.
Bears Say
Pre-revenue Status With Widening Net LossesThe company has no commercial revenues and net losses have widened materially as it scales development. Sustained pre-revenue losses mean the business is consuming capital to advance programs rather than generating returns, creating long-term dependence on successful approval and commercialization.
Negative And Worsening Cash GenerationOperating and free cash flow have become substantially more negative as trials and commercial prep ramp. Persistent negative cash generation increases funding needs and raises the risk of future equity raises or partnerships if timelines extend or unexpected costs arise.
Regulatory And Data-readout UncertaintyFDA guidance requiring completion of Dragon 1 at 2 years and an unknown GA interim readout create structural uncertainty. Additional data requests or unfavorable interim results could delay approval, increase development costs and push back revenue, amplifying execution and funding risk.
Belite Bio, Inc. ADR News
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $59.05 and its highest was $200.00 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $6.10B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is Aug 12, 2026 which is in 33 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on May 20, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.635 by $0.295.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.77.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 39,965,313 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.635. Following the earnings report the stock price went up 2.62%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Belite Bio, Inc. ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$216.20 (30.67% Upside)
$216.20 (30.67% Upside)
Hedge Fund Trend
Decreased
By 584.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.62%
12-Months-Change
Fundamentals
Return on Equity
-26.70%
Trailing 12-Months
Asset Growth
394.07%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Company Deck
BLTE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong program and commercial progress—Phase 3 report received, NDA rolling submission underway, Dragon 2 enrollment completed, substantial commercial hires, and a robust cash position (~$799M). However, the company is incurring sharply higher R&D and SG&A expenses, net losses widened materially, and several clinical and regulatory uncertainties remain (GA interim unknown; FDA guidance requires completion of Dragon 1 at 2 years). On balance the positive development and financial runway outweigh the near‑term expense and uncertainty headwinds.View all BLTE earnings summariesBLTE Stock 12 Month Forecast
Average Price Target
$216.20
▲(30.67% Upside)
Technical Analysis
Denali Therapeutics
―
Kiniksa Pharmaceuticals
―
Beam Therapeutics
―
Harmony Biosciences Holdings
―
―
Ownership Overview
1.03% Insiders
0.81% Mutual Funds
17.21% Other Institutional Investors
80.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---